Pitcairn Co. Has $2.17 Million Stock Position in Cencora, Inc. $COR

Pitcairn Co. cut its stake in Cencora, Inc. (NYSE:COR) by 49.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,945 shares of the company’s stock after selling 6,878 shares during the period. Pitcairn Co.’s holdings in Cencora were worth $2,171,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in COR. Islay Capital Management LLC boosted its stake in shares of Cencora by 6.5% in the 3rd quarter. Islay Capital Management LLC now owns 6,142 shares of the company’s stock valued at $1,920,000 after purchasing an additional 373 shares during the last quarter. KCM Investment Advisors LLC bought a new position in Cencora during the third quarter worth $204,000. Cambria Investment Management L.P. lifted its holdings in Cencora by 37.1% in the third quarter. Cambria Investment Management L.P. now owns 1,212 shares of the company’s stock valued at $379,000 after buying an additional 328 shares during the period. Black Creek Investment Management Inc. boosted its position in Cencora by 15.8% during the third quarter. Black Creek Investment Management Inc. now owns 42,991 shares of the company’s stock valued at $13,436,000 after acquiring an additional 5,851 shares during the last quarter. Finally, AustralianSuper Pty Ltd bought a new stake in Cencora during the third quarter valued at $26,191,000. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Down 2.5%

COR stock opened at $359.05 on Friday. The stock’s 50 day simple moving average is $353.83 and its 200 day simple moving average is $335.69. Cencora, Inc. has a fifty-two week low of $248.59 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The company has a market cap of $69.85 billion, a P/E ratio of 43.16, a price-to-earnings-growth ratio of 1.72 and a beta of 0.68.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. The firm had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm posted $3.73 earnings per share. On average, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio (DPR) is presently 28.85%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Bank of America lowered their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research report on Monday, January 5th. Robert W. Baird set a $415.00 target price on Cencora in a research note on Tuesday, January 13th. UBS Group lifted their target price on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Finally, Barclays raised their price objective on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $399.00.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. This represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 15,220 shares of company stock worth $5,282,867. 0.38% of the stock is owned by corporate insiders.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.